A New Name for a Complex Condition: Why Experts are Renaming PCOS

For many years, millions of women around the world have been diagnosed with a condition called polycystic ovary syndrome, or PCOS. However, after 14 years of global research and collaboration, experts have decided to change the name. The condition will now be known as polyendocrine metabolic ovarian syndrome, or PMOS. This change was announced at the European Congress of Endocrinology in Prague and published in the medical journal The Lancet.

According to The Guardian, this condition affects one in eight women worldwide, totaling about 170 million people. The name change is not just a simple label update; it is a major effort to change how doctors and patients understand the illness. Prof Helena Teede, who led the project at the Monash Centre for Health Research and Implementation, explained that the old name was misleading. She noted that it incorrectly focused only on the ovaries, which often led to delayed diagnoses and poor medical care.

To understand why the name is changing, it helps to look at what the condition actually is. The old name, PCOS, comes from the term "polycystic ovaries." Many people believed this meant there were cysts—small, fluid-filled sacs that can be painful or dangerous—on the ovaries. However, as Prof Colin Duncan from the University of Edinburgh explained to The Guardian, this is not true. What doctors see on an ultrasound are actually follicles, which are structures that contain an egg. In women with this condition, these follicles stop developing before they can release an egg. Because they do not mature, they stay in the ovary, making it look like there are many cysts when there are not.

Experts say the condition is much broader than just the ovaries. It is a hormonal and metabolic disorder. A key part of the condition involves an imbalance of hormones, which are the body's chemical messengers. For example, many people with the condition have high levels of androgens, often called "male sex hormones." While all women have these, having too many can cause symptoms like acne, extra facial or body hair, and irregular periods. Furthermore, about 85% of people with the condition also deal with insulin resistance. Insulin is a hormone that controls how the body uses sugar. When the body is resistant to insulin, it produces more of it, which in turn causes the ovaries to produce even more androgens. This creates a difficult cycle that can lead to weight gain and increase the risk of other health issues, such as diabetes and heart disease.

For patients, the old name often caused confusion. Maddy Mavrikis, who was diagnosed at 15, shared her experience with The Guardian. Her doctor told her she might never have children and insisted she had cysts, even though her tests showed none. She spent years trying to understand a condition that her own doctors could not clearly explain. Mavrikis noted that her mother, who works in the medical field, often questioned why the name focused on ovaries when the symptoms were clearly hormonal. The new name, PMOS, is designed to fix this confusion by highlighting that the condition affects the entire endocrine system—the system that manages hormones—as well as the body's metabolism.

Experts believe that the new name will help doctors see the "multi-system burden" that patients face. By moving away from the focus on ovaries, the medical community hopes to recognize that this is a complex, whole-body condition. While researchers are still studying exactly why this happens, they believe it is a mix of genetics and environmental factors. Some studies suggest that being exposed to high levels of androgens before birth might play a role, while other research focuses on the many genes involved.

Ultimately, the shift to PMOS is about providing better care. By using a name that accurately describes the hormonal and metabolic nature of the illness, experts hope to reduce the confusion that many patients like Mavrikis have faced for years. As the medical community adopts this new term, the goal is to ensure that patients receive faster, more accurate diagnoses and treatments that address the full range of their symptoms rather than just one organ.